 SAN CARLOS, Calif., May 11, 2022 GLOBE NEWSWIRE -- ChemoCentryx, Inc., Nasdaq: CCXI, today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS avacopan, an orally administered selective complement 5a receptor C5aR inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis. 